 Among many non-alcoholic steatohepatitis NASH drug innovators, Madrigal Pharmaceuticals is poised to deliver the first medicine to the market sometime next year. By Q4 this year, the company is anticipated to report data for the Phase 3 MAESTRO-NASH trial. 